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This communication utilises Time-of-Flight Secondary Ion
Mass Spectrometry (ToF-SIMS) combined with multivariate
analysis to obtain spectra from the surfaces of three closely
related cell lines allowing their discrimination based upon mass
spectral ions.
Prostate Cancer (CaP) is the most common male cancer and the
second most common cause of cancer-related death of men in
the UK.1 CaP preferentially metastasises to the bone marrow and
the resulting bone metastases are directly responsible for consider-
able mortality and morbidity. At present, Prostate Specific Antigen
(PSA) is used to identify patients at higher risk of CaP. This is
followed by a biopsy for histopathological assessment using the
Gleason grading system.
It has been shown that the PSA blood test can be misleading in
the diagnosis of prostate cancer2 and a study by Latouff and Saad
showed that Gleason grading varies between pathologists with
identical grades assigned to only 29.2% of tumours.3 The varied
prognostic outcome and need for a robust/intervention therapy
makes CaP an ideal model to develop chemically-based prognostic
indicators.
Time-of-Flight Secondary Ion Mass Spectrometry (ToF-SIMS)
is a surface analysis technique whereby a surface is bombarded
with a high energy (keV) ‘primary’ ion beam. This results in the
ejection, or ‘sputtering’ of ‘secondary’ molecular and fragment ions
that reflect the detailed surface chemistry of the area under
analysis. The secondary ions are analysed using a high sensitivity
time-of-flight mass analyser. Ion flight times are converted into
mass-to-charge (m/z) values using known calibration parameters.
Under atomic primary ion bombardment, the sputter yield of
intact molecular ions or fragments emitted from the top
monolayers is low and chemicals accumulate in the surface region.
Further chemical information on the undamaged surface can only
be obtained up to the so-called ‘static limit’ (corresponding to a
primary ion dose of 1 6 1012 ions cm22), ensuring that a fresh
area is analysed with each primary ion impact. The development of
cluster and polyatomic primary ion beams including Aun
+, Bin
+,
SF5
+ and C60
+ has significantly enhanced the sensitivity of the
ToF-SIMS technique in (bio)molecular analysis.4 Under poly-
atomic bombardment the static limit can in some circumstances be
lifted as the sputter yield is sufficiently high to remove the majority
of surface damage under certain conditions.11 SIMS spectra, like
those derived from other desorption mass spectrometric methods
contain a relatively high degree of fragmentation. The C60
+
primary ion beam used in this study has been shown to increase
the yield of molecular or parent ions from biomolecular samples.5
Although even under C60
+ bombardment the SIMS process does
not typically result in significant yields of high mass biomolecules
(. a few kDa), the key advantages of the technique are its surface
sensitivity (ca. 1–2 nm), high spatial resolution (, mm) and the fact
that the sample does not have to be chemically modified to make it
amenable to analysis. Hence the technique is well suited to
mapping relatively low molecular weight compounds in biological
cells. In this work we explore the capability of ToF-SIMS to
differentiate cells based on surface chemical analysis.
Two prostate cancer cell lines and a prostatic epithelial cell line
were utilised: (1) PC-3, a human prostate cancer epithelial cell line
derived from bone metastases; (2) LNCaP, a human prostate
cancer epithelial cell line derived from lymph node metastases; and
(3) PNT2-C2, an immortalised non-malignant normal adult
prostatic epithelial cell line. Cells were cultured on silicon
substrates in Hams F-12, 7% Foetal Calf Serum (FCS) and
2 mM L-glutamine to 80% confluence at 37 uC in a humidified
atmosphere of 5% CO2 in air. Following culture, cells were washed
for 3 s in phosphate buffered saline (PBS) and for 60 s in deionised
H2O prior to flash-freezing in liquid nitrogen-cooled methyl-2-
butane. The samples were prepared in a Heto Drywinner freeze-
dryer at ca. 1 6 1023 mbar at a temperature of 2110 uC in the
cold trap. ToF-SIMS analysis was carried out on a BioToF-SIMS
instrument6 with a 40 keV C60
+ primary ion beam. Each analysis
was performed over a 5006 500 mm2 field-of-view, corresponding
to a primary ion dose density , 1 6 1010 ions cm22. Charge
compensation was employed using 25 eV electrons between ion
pulses. Positively charged secondary ions in the mass range of 1–
2000 Da were recorded. Fifteen samples, from 15 different cultures
of each cell line were analysed, with three different areas of each
sample analysed. By way of example, Fig. 1 shows a positive ion
mass spectrum taken from a freeze-dried sample of PC-3 cells. This
resulted in a total of 135 mass spectra. The presence of a high level
of sodium can influence the relative intensity of other species in the
ToF-SIMS spectrum through the matrix effect.7 For this reason all
spectra with sodium intensity greater than 10% of the total signal
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were discarded. The resulting filtered spectra, 36 spectra for PC-3,
20 spectra for LNCaP and 32 spectra for PNT2-C2, were pre-
processed by sum-normalisation. This normalises the total area of
the spectrum to one and expresses the peak intensities as a ratio of
that sum.
Principal Component-Discriminant Function Analysis (PC-
DFA) uses Principal Component Analysis (PCA) to reduce
the dimensionality of the data prior to DFA. DFA then
discriminates between groups on the basis of the resulting
PCs and the a priori knowledge of group memberships that are
fed into the DFA algorithm.8 In this case the model uses
44 principal components and two discriminant functions. The
maximum number of discriminant functions available for use
is the number of groups (e.g. number of cell lines) minus one. The
optimum number of principal components was determined
through an iterative process of chemometric model generation
and validation. DFA is a supervised technique, the model is
supplied with information about group membership, so any
result produced by the model needs to be validated. The
model was validated by retaining one-fifth of the total
filtered pre-processed spectra, in this case 17 randomly selected
spectra, and then supplying the spectra to the model as a blind
test and observing where the model places the spectra. Fig. 2A
shows the discriminant function plot showing separation
based upon the training set, Fig. 2B shows the discriminant
training function plot with the training set and blind test set, and
Fig. 2C shows the loadings plots for Discriminant Function 1 and 2
which show the mass spectral peaks responsible for this
discrimination.
Discriminant Function 1 is discriminating the PC-3 cell
line from the PNT2-C2 and LNCaP cell lines, separating the cell
line derived from bone metastases from cell lines derived from
lymph node metastases and normal prostatic epithelial cells.
Discriminant Function 2 is discriminating the PNT2-C2 cell line
from the PC-3 and LNCaP, discriminating the normal prostatic
cell line from the malignant cell lines. Table 1(A) shows the
sensitivities and specificities for the different cell lines at the
95% (pink ellipse) and 99% (green ellipse) confidence limits
based on our validation set (see Fig. 2B). Sensitivity is the
probability of obtaining a positive result from people with
the disease, which is the ability of the model to diagnose.
Specificity is the probability of a negative test among patients
without the disease, or the ability of the model to not misdiagnose.
Table 1(B) shows the proposed mass spectral assignments for
Discriminant Function 1 and Table 1(C) for Discriminant
Function 2. The axes of the discriminant function plot
have positive and negative directions (Fig. 2C). The peaks in
the positive direction of the y-axis of the DF1 loadings
plot correspond to the mass spectral ions which the model
is using to discriminate the LNCaP and PNT2 cell line from
the PC-3 cell line. The peaks in the negative direction
correspond to the mass spectral ions used to discriminate the
PC-3 cell line from the LNCaP and PNT2 cell lines. The
peaks in the positive direction of the DF2 loading plot are
used to discriminate the PC-3 and LNCaP cell lines from the
PNT2 cell line and the peaks in the negative direction are
used to discriminate the PNT2 cell line from the PC-3 and LNCaP
cell lines.
At the 99% confidence limit only one spectrum was misclassi-
fied. A spectrum from the PNT2-C2 cell line was classified as a
PC-3 spectrum. The specificity for the model as a whole is
high and, therefore, it could be said, that the model has the ability
to not misdiagnose. The sensitivity differs for the PC-3 and
LNCaP cell line between the confidence limits, with the greatest
difference seen in the PNT-C2 group. The high sensitivity for the
model at the 99% confidence limit demonstrates the ability to
diagnose.
A detailed interpretation of the mass spectral signatures
associated with chemically complex materials such as biological
cells is very challenging. Chemometric analysis simplifies this task
by highlighting the significant mass spectral difference between
closely related samples, providing a subset of peaks on which the
analyst can focus. In this work, analysis was performed under
static SIMS conditions, in which each primary ion impacts a
previously undisturbed region of the sample. The resulting
mass spectra reflect the outermost molecular layers of the
sample, in this case presumably intact cell membranes. This is
consistent with the appearance of many spectral features that
can be assigned to lipid-related ions. In addition to membrane
lipids a number of amino-acid-related ions are apparent. These
signals may rise from transmembrane proteins. The proposed
assignments point towards a difference in phospholipid
content, with the cancerous cell lines discriminating upon a
phosphocholine or sphingomyelin and the transformed normal
cell line discriminating upon phosphoethanolamine. Elevated
phosphocholine levels have previously been associated with
cellular proliferation, an aspect of cancer.9
This study has shown ToF-SIMS to be capable of cell line
discrimination based upon surface chemical differences. Further
work of this type may assist the identification of potential
diagnostic and prognostic indicators in prostate cancer and
other diseases. The spatial resolution of the ToF-SIMS
technique is such that it is capable of generating mass spectral
data from single cells, as has been demonstrated on numerous
occasions.12 Thus it can be envisaged that the discriminatory
power of the technique demonstrated in this work could
be extended to single cells in a mixed population or tissue
biopsy. Under polyatomic ion bombardment a steady state
Fig. 1 Typical positive SIMS spectrum of PC-3 cell line over a 500 6
500 mm2 area.
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Fig. 2 (A) Discriminant function plot showing separation based upon the training set. 1 = PC-3, 2 = LNCaP, 3 = PNT2. (B) Discriminant function
projection plot with the training set in red and the blind set in blue, showing confidence limits of 95% (pink ellipse) and 99% (green ellipse). 1 = PC-3, 2 =
LNCaP, 3 = PNT2. (C) Loadings plots for Discriminant Function 1 and 2 which show the mass spectral peaks responsible for the discrimination.
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condition may be reached in which the sample is stable to
further ion fluence, facilitating molecular characterisation and
depth profiling beyond the static limit.5 Recently this ToF-SIMS
modality has been applied to biological cells.10 An extension of this
chemometric study to the cellular sub-surface may provide
additional insight into the chemical differences between related
cell lines.
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